Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 ...

A new study may finally change how amyotrophic lateral sclerosis (ALS) is diagnosed. Scientists from UCLA Health and the ...

Cell-free DNA (cfDNA) has emerged as a powerful biomarker for monitoring allograft health and detecting rejection in solid ...

A heart transplant recipient safely carried a baby to term using noninvasive DNA monitoring—marking a new milestone in maternal and transplant care.

Salivary cell-free mitochondrial DNA may serve as a non-invasive, low-cost biomarker for early Alzheimer’s detection before cognitive decline begins.

SAN CARLOS, Calif.--(BUSINESS WIRE)--Elegen, a leader in next-generation cell-free DNA manufacturing, today announced a 25% reduction in price for ENFINIA™ DNA, making industry-leading long, complex, ...

In recent years, the market size for cell-free DNA (cfDNA) kits has expanded swiftly. This market is projected to increase from $1.60 billion in 2024 to $1.80 billion in 2025, marking a compound ...

Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? Dear M.N.: When screening patients for ...

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Channing Paller discussing germline and somatic genetic ...